Syngene International, an India-based global contract research, development, and manufacturing organisation (CRDMO), announced on Tuesday that it has extended its long-standing strategic collaboration with US biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) to 2035.

According to Syngene, the expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialisation.

Peter Bains, managing director and CEO of Syngene International, said: "Our collaboration with Bristol Myers Squibb, which now spans more than 25 years, is anchored in scientific excellence, operational reliability, and a shared commitment to advancing innovative therapies. The agreement to extend this partnership through 2035 enables us to plan together for the future in terms of building new capabilities and infrastructure with a decade long horizon. Taking a long-term perspective is a key feature of our partnership which adds strategic value to both companies."